Crescent Biopharma reports Q3 EPS ($1.27), two est. ($1.38)

“We have made exciting progress during 2025 advancing our pipeline of next generation therapeutics for solid tumors toward the clinic,” said Joshua Brumm, chief executive officer of Crescent. “For CR-001, our PD-1 x VEGF bispecific antibody, we are presenting preclinical data at SITC demonstrating cooperative pharmacology and in vivo anti-tumor activity. We are thrilled with the engagement from clinicians who share our enthusiasm for CR-001 and plan to commence our global Phase 1 trial in patients with solid tumors in the first quarter of 2026 with initial data anticipated later next year. In addition, we continue to progress our ADC programs and expect to submit an IND for CR-002 in mid-2026. We remain focused on executing across the business with the goal of delivering the next wave of transformative therapies for people living with cancer.”